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Introduction
The increasing morbidity and unsatisfactory effects of
treatment, especially in cases of advanced laryngeal
carcinoma, stimulate the researchers to develop new
more effective chemotherapy schemes within the radi-
cal combined treatment. 
The role of chemotherapy as a part of the radical
treatment for advanced head and neck cancer is still
controversial [1]. Optimal drug combination and
sequence of  chemotherapy to other methods are
unknown. It seems that creating a model that may be
used to evaluate the reactivity of laryngeal carcinoma
cells to the cytostatic planned in therapy in vitro may
help to choose a suitable cytostatic and contribute to
the improvement of therapeutic effects in this type of
cancer. 
Almost 35 years ago, Kerr et al. suggested that
apoptosis would be pronounced in tumors subjected to
the action of selected agents such as irradiation or
cytostatic drugs [2]. At present apoptosis is known to
be induced in tumor cells by multiple  cytostatic drugs
of a variable chemical structure and different mecha-
nisms of action. The product of P53 tumor suppressor
gene has been implicated as a critical factor in the reg-
ulation of this process mediated by DNA damaging
agents, because of its involvement in the control of
genetic stability [3]. The first proto-oncogene shown
to be involved in the regulation of apoptosis was BCL-
2 [4]. The BCL-2 protein can inhibit apoptosis trig-
gered by different cytotoxic agents.
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Abstract: Unsatisfactory effects of treatment of laryngeal carcinoma patients stimulate the clinicians as well as researchers
to develop new more effective treatment models and to find new reliable prognostic factors. The aim of the present study
was the evaluation of the use of primary cell cultures of the laryngeal carcinoma and laser scanning cytometry (LSC) in the
assessment of tumor reactivity to cisplatinum. Nineteen primary cultures of laryngeal carcinoma cells established from
fragments of laryngeal carcinoma infiltrations were cultured with or without cisplatin, stained with monoclonal antibodies
against P53 and BCL-2 proteins and analyzed by LSC. Cisplatin added to the culture medium leads to the significant
increase of P53 expression and decrease of BCL-2 expression. Moreover, changes of P53 and BCL-2 expressions were sig-
nificantly correlated. Our findings of apoptosis regulatory mechanisms could be useful in patient qualification for the
chemotherapeutic follow-up treatment.
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Cisplatin (cis-diamminedichloroplatinum; CDDP)
is one of the most potent and useful antitumor agents
for the treatment of malignant solid tumors. The acti-
vated compound reacts with cellular DNA to form
interstrand and intrastrand crosslinks. Itrastrand
crosslinks inhibit DNA replication and RNA transcrip-
tion, leading to DNA breaks and miscoding that are
either mutagenic or lethal for the affected cell [5].
The aim of the study was the evaluation of the use
of primary cell cultures of the laryngeal carcinoma and
laser scanning cytometry in the presentation of tumor
reactivity to cisplatinum. Changes in the  expression of
P53 and Bcl-2 protein were assumed as reactivity indi-
cator.
Material and methods
Sample material. Primary cultures of laryngeal carcinoma cells
were established from fragments of laryngeal carcinoma infiltra-
tions, collected from 19 patients immediately after laryngectomy.
The method of growing the cultures of laryngeal carcinoma cells is
presented in details in our earlier study [6].
The method of growing the cultures of laryngeal carcinoma
cells. The material intended for the cell culture establishment was
collected aseptically from laryngeal carcinoma infiltration, direct-
ly after laryngectomy. The fragment of the cancer tissue was trans-
ferred onto sterile Petri dish and cleared from clotted blood and
visible necrotic tissue.
After 5 min. washing in culture medium (MEM) (Gibco BRL),
the tissue was divided into several parts which were placed in
antibiotic solution (300 U/ml penicillin, 300 μg/ml streptomycin,
0.75 μg/ml amphotericin B, 25 μg/ml tylosin, 300 μg/ml
kanamycin) (Sigma). After 1 hour of incubation at room tempera-
ture the fragments were washed in culture medium without antibi-
otics and transferred onto new sterile Petri dish. The material was
then crumbled with scissors and  culture medium supplemented
with 10% fetal bovine serum (FBS) and antibiotics (100 U/ml
penicillin, 100 μg/ml streptomycin and 0.25 μg/ml amphotericin
B) was added to the small tissue parts (<0.1 mm3).The tissue sus-
pension was transferred into wells of the Lab-Tek chamber slide
(8-well) (Nunc.) and cultured at 37°C with 5% CO2 incubator for
2-4 weeks. 
The expression and BCL-2 and P53 protein  was estimated in
tumor cell outgrowths from single tissue fragments adhered to the
bottom surface of the well.
Immunohistochemistry. Before the basic immunocytochemical
determination of P53 and BCL-2 was performed, the presence of
squamous epithelium carcinoma cells was confirmed in each cul-
ture by carrying out the immunocytochemical test with a mono-
clonal antibody - cytokeratin (clon MNF116) produced by DAKO
directed toward keratin filaments.
In the first stage of carrying out the immunocytochemical reac-
tion the cell cultures were washed twice with PBS and fixed for 15
min. in 0.25% paraformaldehyde in the dark at room temperature.
After the next washing with PBS, glass slides  with cultures were
immersed in 75% methanol for 24 hours at +4°C. Cultures were
rehydrated and incubated with mice monoclonal antibodies direct-
ed toward human P53 (Do-7; Dako, Glostrup, Denmark), working
concentration 1:25, and Bcl-2 (124, Dako), working concentration
1:20; at room temperature for 1 hour. After washing with PBS cul-
tures were incubated for 1 hour with anti-mice secondary antibody
conjugated with FITC. Cell cultures were washed again with PBS
and, in order to stain DNA, propidine iodide (5 µg/ml) was added
in the presence of RNAse (100 µg/ml) and slides were incubated
for 30 min. at room temperature. After the last washing specimens
were mounted with glycerol and covered with a cover glass.  
Methods of measurement of P53 and BCL-2 expression in pri-
mary cultures of laryngeal carcinoma. The measurement of P53
and BCL-2 expression was performed using a laser scanning
cytometre CompuCyte LSC (CompuCyte Inc., Cambridge, Massa-
chusetts). Specimens were evaluated in LSC immediately after
their preparation. Fluorescence was induced using argon laser light
of 488 nm wave length. PI and FITC fluorescence were exited by
488-nm laser and measured by separate photomultipliers using
standard dichroic mirrors and emission filters. Entire slides were
scanned. Threshold contour was set on PI fluorescence enabling to
separate nuclear fluorescence. Total green fluorescence was meas-
ured within the integration contour (which was enlarged to cover
all specific fluorescence). Cisplatinum treated and untreated cell
cultures were located in the same slides and were subjects of the
same staining procedures. All details of the method were described
in our previous study [13,14].
Statistical analysis. The statistical analysis of the collected mate-
rial was carried out using STATISTICA 6.0. programme. The
change in the expression of studied proteins after the incubation of
the primary cell cultures with cisplatinum was evaluated using the
Wilcoxon significance test. The evaluation of dependence between
the changes in the expression of P53 protein and changes in the
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Table 1. The expression of P53 and BCL-2 protein in laryngeal
carcinoma cell cultures with and without cisplatinum treatment.
expression of BCL-2 protein in the primary cultures after the incu-
bation with cisplatinum was carried out using the accurate Fisher
test and the Spearman test for the correlation coefficient . 
Results
A total of 35 specimens were obtained for evaluation,
and 19 of them (54%) were grown in vitro.
Statistically significant increase in the  expression
of P53 protein   in studied cultures, after the incubation
with cisplatinum in the dose of 0.5 μg/ml, was con-
firmed by the analysis of results using par Wilcoxon
sequence test (T=40.00, p<0.05), which is presented in
Fig.1. The increase in the expression of P53 protein
was observed in 14 out of 18 primary cultures of laryn-
geal carcinoma after the incubation with cisplatinum.
In the remaining 4 cultures the decrease in the expres-
sion of P53 was observed (Table 1).    
The decrease in the expression BCL-2 protein was
found in 6 out of 13 cultures and the increase in BCL-
2 in the remaining 7 cultures (Table 1). 
The increase in the expression of P53 protein was
accompanied by the decrease in the level of Bcl-2 pro-
tein in cell cultures of laryngeal carcinoma after the
incubation with cis-platinum. In 9 cultures, where the
expression of P53 protein in the cells increased after
administering cytostatic, the increase in the level of
cell protein BCL-2 was found in 3 cultures (33.3%)
and the decrease in 6 cultures (66.6%). The Spearman
test for the correlation coefficient confirmed a signifi-
cant correlation between changes in the expression of
P53 protein and changes in the expression of BCL-2
protein after the incubation with cis-platinum (r=-
0.7972, p<0.005) (Fig.2). It was also confirmed by the
accurate Fisher test (p<0.05).
Discussion
Experiments performed on primary cell cultures in
vitro are currently one of the most popular and effec-
tive methods to test the expression of selective mark-
ers on tumor cells or analyze cell sensitivity to new
substances or clinically used cytostatics. The results
could be useful in choosing the kind and dose of drugs
that might be administered  to the patient [8]. Howev-
er, such analysis should be applied only as preliminary
studies and should be considered as screening tests.
However, many oncologists begun to accept the results
of immunocytochemical staining of primary cell cul-
tures as an additional and helpful method beside
immunohistochemical paraffin-embedded tissue sec-
tion analysis, which may be used in modern pathology.
Moreover, the advantage of primary tumor cell culture
is the unchanged membrane and cytoplasmic marker
expression that closely reflects the origin of tissue.
Therefore, the results of e.g. P53, BCL-2 and synde-
can-1 expression on primary tumor cells in vitro
enable to foresee potential resistance or sensitivity of,
e.g. laryneal carcinoma cells to planned chemotherapy.
There are several techniques for the culture of  can-
cer cells [6,9,10]. This study  presents that laryngeal
cancer may grow in a liquid overlay system. Squa-
mous cell carcinoma of larynx was successfully cul-
tured from 21 of 39 specimens (54%). The vast major-
ity of specimens that did not grow were taken directly
from primary tumors of the larynx. This is not surpris-
ing because the tumors are frequently necrotic and
grossly infected. Gêbarowski et al. reported that they
developed 45 cultures from 65 solid tumors (70%) but
Mattox et al. successfully cultured 33 from 75 speci-
mens (45%) [8,10].
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Fig. 1. Expression of P53 protein in
primary cell cultures of laryngeal
carcinoma before and after the
incubation with cisplatinum in the
dose of 0.5 μg/ml.
It should be emphasized, that adaptation of LSC in
the present study to measure individual colonies
enables to measure the expression of P53 and BCL-2
of the clone in situ, without detaching and dispersing
the cells which is required for example when the meas-
urement  is taken by the flow or image cytometry. The
cultures were set up using commercially available
chambers based on microscope slides. This enabled us
to fix and stain the colonies on the same slides, which
were then directly subjected to fluorescence measure-
ments by LSC. The cells were then intact, not enzy-
matically injured and expressing proteins similarly to
the original tissue.
Our study reveals that the  expression of  P53 is
increased in 14 of 18 laryngeal carcinoma cell cultures
after the incubation with cisplatinum (0.5 μg/ml). The
BCL-2 changes, however, were variable after the incu-
bation with cisplatinum, the increased expression of
BCL-2 was observed in 6 and the decreased expression
of BCL-2 was expressed in 7 cultures. There were also
interdependencies between the  increased P53 and
decreased expression of BCL-2 in 5 primary laryngeal
carcinoma cell cultures after cisplatinum administra-
tion.
Recent studies have demonstrated that at least two
pathways regulate apoptosis: one dependent on the
tumor suppressor gene P53 and the other P53-inde-
pendent [11,12]. 
Cisplatinum has been reported to activate P53, as a
response to the formation of DNA inter- and intra-
stand cross-links [15]. Many studies have described
cell cycle effects induced by cisplatinum, the inhibited
progression through S phase and the block in G2M
being the principal perturbations [16]. After long treat-
ment with high concentrations of the drug, an addi-
tional block in G1 was detected together with the cell
death distributed in all cell cycle phases [17]. G1 arrest
induced by cisplatinum has been reported to be P53-
independent [18].
The effects of cisplatinum on cell apoptosis have
been investigated in a number of human cancer cell
lines.
Ikeguchi et al. reported the increase of expression of
P53 protein in one of four investigated gastric cancer
cell lines after the incubation with cisplatinum and
decrease in BCL-2 protein expression in other investi-
gated cancer cell lines. After the incubation with cis-
platinum, apoptotic cells were detected more frequent-
ly among cells with a wild-type gene for P53 and with-
out expression of the BCL-2 protein than among cells
with a mutant or complete deletion of the gene for p53
and with overexpression of BCL-2 protein [19].
Yip HT et al. observed in two of three investigated
carcinoma cell lines of head and neck cancers the
increased expression of p53, p21, p16, BCLxL, and
BCLxS genes with cisplatinum treatment. Expression
of p27, DP1, MDM2, BCL-2, c-iun and jun-D
remained unaltered after treatment [20]. 
P53 status or BCL-2 expression have been impli-
cated as useful predictors of chemosensitivity of ovar-
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Fig. 2. Correlation between the
change in the expression of P53
protein and the change in the
expression of BCL-2 protein in pri-
mary cell culture of laryngeal carci-
noma after the incubation with cis-
platinum (r=-0.7972, p<0.005).
ian carcinoma [21] or resistance [22]. In vitro, p53
mutations were associated with down-regulation of
Bax, a protein promoting apoptosis in the IGROV-1/Pt
cells [21].
The human tumor culture assay has proved to be an
important adjunct in the management of ovarian carci-
noma, myeloma, and melanoma. In a group of heavily
pretreated patients, this system correctly predicted sen-
sitivity to cancericidal drugs with 62% accuracy and
resistance with 96% accuracy [23]. Therefore,
although in vitro sensitivity does not guarantee the
same results in patients, generally in vivo resistance is
a strong argument for the selection of another
chemotherapeutic agent.
On the other hand Burger et al. and Perego et al.
suggested that at least in their panel of tumor cell lines,
hypersensitivity or resistance to cisplatin might not be
necessarily correlated with the presence of wild-type
of P53 and probably not associated with BCL-2 and
Bax expression [7,24].
Our results obtained in primary cultures of laryn-
geal carcinoma cells  with the use of laser scanning
cytometry reveal that in this way it is possible to
determine very precisely the tendency and the extend
of changes in the expression of P53 and BCL-2 in
these carcinoma cells after the incubation with cis-
platinum. The correlation between the expression of
P53 and Bcl-2 protein, found in a certain number of
studied cultures, indicates that in these cultures P53
dependent apoptosis is induced after the incubation
with cisplatinum. It seems that the model  for the
evaluation of the expression of P53 and BCL-2 pro-
tein in primary cells of laryngeal carcinoma using
laser scanning is helpful for the evaluation of reactiv-
ity of laryngeal carcinoma to a cytostatic adminis-
tered in  vitro. 
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